Abiomed Archives | Be Korea-savvy
Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%

Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%

DANVERS, Mass., Oct. 26 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of $132.8 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. Second quarter fiscal 2018 GAAP net income was $24.5 million [...]

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure

DANVERS, Mass., Sept. 20 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption [...]

Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant

Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant

DANVERS, Mass., Aug. 28 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017.  After two years, Mr. Tomsicek is leaving the Company to pursue other interests. While the Company performs [...]

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year

DANVERS, Mass., Jul. 27 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million [...]

Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study

Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study

DANVERS, Mass., May 4 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door to Unloading (DTU) with Impella CP® system in acute myocardial infarction. This trial will focus on [...]

Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year

Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year

DANVERS, Mass., May 4 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2017 revenue of $124.7 million, an increase of 33% compared to revenue of $94.0 million for the same period of fiscal 2016.  For fiscal year 2017, total revenue was $445.3 million, up [...]